Showing Results for: “diabetes exercise”

The ADA asks you to raise your voice, mark your fist and share your image on social media using #CountMeInADA This November, the American Diabetes Association (ADA) is highlighting the numbers that matter most when it comes to those living with, at risk and supporting those with diabetes. Count Me In is not just an awareness campaign; it is a call to action for all of us. Visit diabetes.org/CountMeInADA to answer the call today. On November 1st, to kick off American Diabetes Month, show your solidarity, whether you have diabetes, you’re supporting someone who has it, or you’re a caregiver

Social Determinants of Health grant will provide community gardens and diabetes support to people in low-income areas in Alabama The American Diabetes Association® (ADA) and The Pfizer Foundation have joined forces to address food insecurity and high rates of diabetes in communities in Montgomery, Alabama. The Foundation grant is part of ADA’s Health Equity Now national platform to ensure that all people living with diabetes, and the millions of underserved Americans who are at greatest risk for diabetes, have equal access to resources that they require not just to survive, but to thrive. The

The #NourishMyHealth public education campaign to be featured at the ADA's Tour de Cure ® and Step Out Walk to Stop Diabetes ® events Today, the National Association of Chain Drug Stores (NACDS) announced they are teaming up with the American Diabetes Association ® (ADA) during the ADA's Tour de Cure ® (cycling event) and Step Out Walk to Stop Diabetes ® (walking event) to provide critical nutrition education to the event participants. Running through the end of 2024, the cycling and walking events will feature #NourishMyHealth, a campaign designed to educate Americans on the protective health

On October 5, 2021, Medtronic announced the expansion of two recalls on MiniMed 600 series insulin pumps for incorrect insulin dosing and remote controllers used with Paradigm and 508 MiniMed insulin pumps for potential cybersecurity risks. The U.S. Food and Drug Administration (FDA) has identified both of these as Class I recalls, the most serious type of recall. People with diabetes who are currently using a MiniMed 600 series insulin pump and are unsure if their device is affected, should refer to the Medical Device Recalls database or use the Medtronic Pump Serial Number Look-up Tool . If

People with type 2 diabetes should be considered in remission after sustaining normal blood glucose (sugar) levels for three months or more, according to a new consensus statement from the American Diabetes Association ® (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK jointly published in Diabetes Care , the J ournal of Clinical Endocrinology & Metabolism , Diabetologia , and Diabetic Medicine , respectively. About 10% of the U.S. population has diabetes , and these numbers continue to rise. People with type 2 diabetes can achieve “remission” by

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the

Participating, approved products will display the mark on select products to inform consumers The American Diabetes Association (ADA) is pleased to announce the launch of the Better Choices for Life program. The program is designed to aid shoppers in making better choices while shopping and is currently in its pilot stage. Products are selected through a science and evidence-based approach. At this time, prescription drugs are not evaluated or considered for the program. Following an extensive evaluation process, companies applying for participation and passing the evaluation may place the

Analysis of large international DAPA-HF trial participants notes diabetes prevention benefit in patients with heart failure who took 10 mg of medication The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D), according to the study, “Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF,” presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. The original DAPA-HF trial was a phase 3 placebo-controlled international study of

Today, the American Diabetes Association® (ADA) released its 2023 Research Report , highlighting investments in advancing diabetes research and clinical practice. ADA research grants focused on innovative projects with high impact and helped researchers establish collaborative networks to move their innovations into the hands of people living with diabetes. “Research at the ADA is the engine that drives clinical advances by catapulting them into practice. 2023 has brought many prominent achievements. We are incredibly proud of our legacy of highlighting science and eager to build on this